Effect of Intranasal Ginsenoside Rb1 Against Epilepsy in Mice Induced by Chronic Ignition of Pentylenetetrazole
10.13422/j.cnki.syfjx.20221908
- VernacularTitle:人参皂苷Rb1经鼻给药对戊四唑慢性点燃小鼠的抗癫痫作用
- Author:
Juan LI
1
;
Yushu LIU
1
;
Ying LIU
1
;
Xi WANG
1
;
Minke TANG
1
Author Information
1. School of Chinese Materia Medica， Beijing University of Chinese Medicine，Beijing 102488，China
- Publication Type:Journal Article
- Keywords:
epilepsy;
intranasal administration;
ginsenoside Rb1;
pentylenetetrazole （PTZ）
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2022;28(24):65-74
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo observe the effect of intranasal ginsenoside Rb1 against epilepsy and preliminarily explore the mechanism. MethodThe mouse model of chronic epilepsy was established by intraperitoneal injection of pentylenetetrazole （PTZ）. After successful modeling （21 d）， the epileptic mice were randomly divided into PTZ group， sodium valproate （VPA） group， and low-dose （20 mg·kg-1） and high-dose （40 mg·kg-1） ginsenoside Rb1 groups. Mice in each group were given corresponding drugs intranasally for 30 days， twice a day， and the control group was given the equal volume of normal saline. During the intranasal administration， the weight change， epilepsy latency， and epilepsy stage of the mice were recorded， and the changes in the electroencephalography （EEG） were recorded wirelessly. Neuronal Nuclei （NeuN） was used to observe the damage of neurons in cerebral cortex and hippocampus. The activation of microglia and astrocytes was observed with ionized calcium binding adapter molecule-1 （IBA-1） and glial fibrillary acidic protein （GFAP）， respectively. Glutamate （Glu） transporter-1 （GLT-1） and glutamine synthetase （GS） were used to observe the key molecular changes in Glu regulation. ResultCompared with the control group， the PTZ group decreased body weight （P<0.05，P<0.01）， shortened the epilepsy latency （P<0.01）， and increased the epilepsy stage （P<0.01）. The epileptic EEG waves were increased in the PTZ group. Compared with the PTZ group， the low and high-dose ginsenoside Rb1 groups increased body weight （P<0.05，P<0.01）， prolonged the epilepsy latency （P<0.05，P<0.01）， decreased the epilepsy stage （P<0.05，P<0.01）， and decreased epileptiform EEG waves. Immunofluorescence staining （IF） showed that ginsenoside Rb1 significantly ameliorated PTZ-induced neuronal damage （P<0.05，P<0.01） in the motor sensory area of the cerebral cortex and hippocampal CA1 area， and significantly inhibited PTZ-induced activation of microglia （P<0.05，P<0.01） and astrocytes. Further research found that ginsenoside Rb1 significantly improved the expressions of astrocytic GLT-1 （P<0.01） and GS （P<0.01） in the brains of epileptic mice. ConclusionIntranasal ginsenoside Rb1 can significantly improve the symptoms of epilepsy caused by PTZ in mice， which has a clear protective effect on neuronal damage in the brains of epileptic mice and significantly inhibits the activation of brain microglia and astrocyte activation. Its anti-epileptic mechanism may be related to the regulation of GLT-1 and GS of the key molecules of astrocyte Glu metabolism.
